Dr. Birnbaum is an independent consultant specializing in the development of dermatological products. His clients include pharmaceutical companies, venture capitalists, and universities. He has over 25 years of industry experience spanning the areas of discovery research, formulations, clinical R&D, regulatory, and marketing, and he has been involved in commercializing numerous drug and consumer skin care products. Dr. Birnbaum was previously Vice President at Novartis Pharmaceuticals Corporation, where he played a key role in the development and launch of Lamisil.

Dr. James Baker, NanoBio's Chief Science Officer and Acting CEO, comments, "Dr. Birnbaum brings expertise to NanoBio that will be important for the commercialization of our entire product line. His experience in the development of Lamisil will be particularly valuable as NanoBio proceeds with the clinical development of it nail fungus treatment, NanoTxt(tm).

Other NanoBio SAB members include:

Blake Roessler, M.D., is an Associate Professor in the University of Michigan (U-M) School of Medicine's Department of Internal Medicine (Division of Rheumatology). He is Director of the U-M's Human Applications Laboratory. Dr. Roessler is board-certified in infectious diseases and rheumatology. He is an expert in clinical development of novel human therapeutics and regulatory matters.

Lawrence R. Stanberry, M.D., Ph.D., is the Chief of Pediatrics and Director of the Sealy Center for Vaccine Development at the University of Texas Medical Branch in Galveston. Dr. Stanberry is internationally recognized for his work in the development of vaginal microbicides and vaccines for the prevention of genital herpes.

Norman Weiner, Ph.D., is a Professor Emeritus of the U-M's College of Pharmacy, where he conducted pharmaceutical research for nearly 30 years.
Dr. Weiner was previously a Professor of Pharmacy at Columbia University, and is an extensively published authority on therapeutic-based emulsion technology.

Shaun Jones, M.D., is a Senior Scientist with the U.S. Navy Medical Corps, and an expert in biotechnology development and commercialization.

David A. Relman, M.D., is a Professor of Medicine and head of the Infectious Disease, Microbiology, and Immunology Division at the Stanford University Veterans Administration Medical Center. Dr. Relman is a worldwide expert in infectious diseases and emerging infectious diseases.

Company Background:

NanoBio Corporation is a biopharmaceutical company whose mission is to develop and commercialize topical and mucosal pharmaceuticals based on its patented antimicrobial nanoemulsion technology. The technology was developed at the University of Michigan Medical School. NanoBio, a privately held corporation, is the exclusive licensee of this technology.

NanoBio has begun patient enrollment for FDA-approved Phase II clinical trials for NanoHPX, a new topical treatment for Herpes Labialis. In addition, clinical trials are scheduled to begin late this year with NanoTxt(tm), which is a topical treatment for nail fungus (onychomycosis).

NanoBio's product has the potential to be the first topical treatment for nail fungus with efficacy similar to systemic medications.

Additional longer-term products in development include treatments for genital herpes and shingles, and a broad-spectrum vaginal infection treatment that is efficacious against fungal, bacterial, and parasitic infections. NanoBio's products have important therapeutic, safety, and cost advantages over currently available treatments.

Contact: John Coffey, VP Business Development, NanoBio Corporation 734.302.4000 x107, john.coffey@nanobio.com; www.NanoBio.com

Lamisil( is a registered trademark of Novartis Pharmaceutical, Inc.